000 | nab a22 7a 4500 | ||
---|---|---|---|
999 |
_c16978 _d16978 |
||
003 | PC16978 | ||
005 | 20220824112425.0 | ||
008 | 220824b xxu||||| |||| 00| 0 eng d | ||
040 | _cH12O | ||
041 | _aspa | ||
100 |
_9433 _aSepúlveda Sánchez, Juan Manuel _eOncología Médica |
||
245 | 0 | 0 |
_aEl receptor del factor de crecimiento epidérmico (EGFR) en el glioblastoma: mecanismo de tumorigénesis y papel como diana terapéutica. _h[revisión] |
260 |
_bRevista de neurología, _c2015 |
||
300 | _a61(2):85-93. | ||
500 | _aFormato Vancouver: Zahonero C, Sepúlveda JM, Sánchez Gómez P. El receptor del factor de crecimiento epidérmico (EGFR) en el glioblastoma: mecanismo de tumorigénesis y papel como diana terapéutica. Rev Neurol. 2015 Jul 16;61(2):85-93. | ||
501 | _a PMID: 26156444 | ||
504 | _aContiene 81 referencias | ||
520 | _aA glioblastoma is a primary brain tumour that is very aggressive and resistant to conventional treatment with chemo- or radiotherapy. Given that epidermic growth factor receptor (EGFR) is altered in 50% of glioblastomas, it is currently one of the most promising therapeutic targets in this kind of tumour. Yet, inhibitors of the kinase activity of EGFR have yielded poor results in clinical trials with patients with glioblastomas. In this review we analyse the function of EGFR in glioblastomas and outline the therapeutic approaches aimed against this receptor in this kind of tumour. This sort of analysis could be a starting point for improving the design of future therapies for glioblastomas, based on inhibiting the EGFR function. | ||
710 |
_9303 _aServicio de Oncología Médica |
||
856 |
_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc16978.pdf _ySolicitar documento |
||
942 |
_2ddc _cREV _n0 |